{"id":50651,"date":"2022-11-09T14:02:05","date_gmt":"2022-11-09T13:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/"},"modified":"2022-11-09T14:02:05","modified_gmt":"2022-11-09T13:02:05","slug":"alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/","title":{"rendered":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences"},"content":{"rendered":"<div>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=52964337&amp;newsitemid=20221109005152&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=e0281fd14187eafda47b0f4579554c05\" rel=\"nofollow noopener\" shape=\"rect\">Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/5\/Alnylam_Corporate_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nJefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London\n<\/li>\n<li>\nStifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:15 pm ET at the Lotte New York Palace Hotel in New York City\n<\/li>\n<li>\nEvercore ISI 5<sup>th<\/sup> Annual HealthCONx Conference on Tuesday, November 29, 2022 at 1:50 pm ET being held virtually\n<\/li>\n<li>\nPiper Sandler 34<sup>th<\/sup> Annual Healthcare Conference on Wednesday, November 30, 2022 at 9:30 am ET at the Lotte New York Palace Hotel in New York City\n<\/li>\n<\/ul>\n<p>\nA live audio webcast of each presentation will be available on the Investors section of the Company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.alnylam.com%2Fevents&amp;esheet=52964337&amp;newsitemid=20221109005152&amp;lan=en-US&amp;anchor=www.alnylam.com%2Fevents&amp;index=2&amp;md5=87730420d37d6a3099953f2f849e60ec\" rel=\"nofollow noopener\" shape=\"rect\">www.alnylam.com\/events<\/a>. A replay will be available on the Alnylam website within 48 hours after each event.\n<\/p>\n<p>\n<b>About Alnylam Pharmaceuticals<br \/>\n<br \/><\/b><i>Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam\u2019s commercial RNAi therapeutic products are ONPATTRO<sup>\u00ae<\/sup> (patisiran), GIVLAARI<sup>\u00ae<\/sup> (givosiran), OXLUMO<sup>\u00ae<\/sup> (lumasiran), AMVUTTRA<sup>\u00ae<\/sup> (vutrisiran) and Leqvio<sup>\u00ae<\/sup> (inclisiran) being developed and commercialized by Alnylam\u2019s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its \u201cAlnylam P<sup>5<\/sup>x25\u201d strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline<\/i><i>, please visit <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=52964337&amp;newsitemid=20221109005152&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=3&amp;md5=46699eaf01e199a22f843e4bb23ae048\" rel=\"nofollow noopener\" shape=\"rect\">www.alnylam.com<\/a><i> and engage with us on Twitter at <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAlnylam&amp;esheet=52964337&amp;newsitemid=20221109005152&amp;lan=en-US&amp;anchor=%40Alnylam&amp;index=4&amp;md5=16d30719b8a9a739c4c0f5b3033ce64c\" rel=\"nofollow noopener\" shape=\"rect\">@Alnylam<\/a><i>, on <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F48171%2F&amp;esheet=52964337&amp;newsitemid=20221109005152&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=90901b6d7ec919d11eff371c95fc4ad6\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a><i>, or on <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Falnylampharma%2F&amp;esheet=52964337&amp;newsitemid=20221109005152&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=3a2fd4b92113bf2060636d87df986ae7\" rel=\"nofollow noopener\" shape=\"rect\">Instagram<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nAlnylam Pharmaceuticals, Inc.<br \/>\n<br \/>Christine Regan Lindenboom<br \/>\n<br \/>(Investors and Media)<br \/>\n<br \/>617-682-4340\n<\/p>\n<p>\nJosh Brodsky<br \/>\n<br \/>(Investors)<br \/>\n<br \/>617-551-8276\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50651","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T13:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alnylam to Webcast Presentations at Upcoming November Investor Conferences\",\"datePublished\":\"2022-11-09T13:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/\"},\"wordCount\":362,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005152\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/\",\"name\":\"Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005152\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"datePublished\":\"2022-11-09T13:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005152\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221109005152\\\/en\\\/1161817\\\/21\\\/Alnylam_Corporate_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam to Webcast Presentations at Upcoming November Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Pharma Trend","og_description":"CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-09T13:02:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences","datePublished":"2022-11-09T13:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/"},"wordCount":362,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/","name":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","datePublished":"2022-11-09T13:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221109005152\/en\/1161817\/21\/Alnylam_Corporate_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alnylam to Webcast Presentations at Upcoming November Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50651"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50651\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}